Abstract:Major depressive disorder(MDD) is a kind of mental disorder with depression and decreased interest as the main clinical manifestations. The pathogenesis of MDD is unclear, and MDD is characterized by high incidence, high recurrence rate and high suicide rate. At present, the hypothesis of monomamine mechanism can not fully clarify its pathological characteristics, and a considerable number of patients with depression do not respond well to existing antidepressants. N-methyl-D-aspartate receptor (NMDAR) antagonist and γ-aminobutyric acid A(GABAA) receptor positive allosteric regulator have a potential rapid antidepressant effect, which may be a breakthrough in the pathogenesis and clinical treatment of depression. NMDAR has bidirectional regulation, when proper activation of NMDAR can promote dendrite development, neuronal growth and long-term potentiation, but overstimulation of NMDAR can cause toxic reaction, leading to synaptic atrophy and neuronal death. In addition, inflammation can induce changes in NMDAR function and lead to depressive symptoms. At present, ketamine, a new antidepressant NMDAR antagonist, may plays a role in rapid antidepressant and delayed recurrence of depression by increasing the release of BDNF, activating the signal pathway of mammalian target of rapamycin complex 1(mTORC1), and promoting protein synthesis and synaptic plasticity. Thus, ketamine has the effect of rapid antidepressant and delaying the recurrence of depression. However, due to the large variability of NMDAR gene in patients with MDD, its potential functional polymorphism affects clinical symptoms and drug sensitivity. Therefore, by analyzing the latest research at home and abroad, this review comprehensively summarizes the pathogenesis of NMDAR dysfunction, the pathogenesis of MDD, antidepressant treatment and clinical application status, in order to provide theoretical basis for clinical accurate treatment of MDD patients in the future.

Dysfunction of Glutamatergic Synaptic Transmission in Depression: Focus on AMPA Receptor Trafficking

Targeting the dysfunction of glutamate receptors for the development of novel antidepressants

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression

Cortical Functional Hyperconnectivity in a Mouse Model of Depression and Selective Network Effects of Ketamine

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Targeting of NMDA Receptors in the Treatment of Major Depression.

A Bright Future of Researching AMPA Receptor Agonists for Depression Treatment

GluN2A: A Promising Target for Developing Novel Antidepressants

Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders]

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity

Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine

Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants

Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

N-methyl-D-aspartic receptor and major depressive disorder

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Molecular Mechanisms of AMPA Receptor Trafficking in the Nervous System